What is the proper protocol for ordering amphotericin B (antifungal medication)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The proper protocol for ordering amphotericin B involves specifying the exact formulation and dosing, with conventional amphotericin B deoxycholate typically dosed at 0.5--1.5 mg/kg administered once daily intravenously, as recommended by the CDC and the Infectious Diseases Society of America 1. When ordering amphotericin B, it is crucial to clearly indicate whether you're prescribing conventional amphotericin B deoxycholate or one of the lipid formulations, such as liposomal amphotericin B, amphotericin B lipid complex, or amphotericin B colloidal dispersion.

Key Considerations for Ordering Amphotericin B

  • The recommended amphotericin B regimen is 0.5--1.5 mg/kg administered once daily intravenously, with the option to initiate at lower doses (0.25--0.5 mg/kg) in patients with mild-to-moderate disease and increase as tolerated 1.
  • Amphotericin B should be administered in 5% dextrose in water to give a final concentration of 0.1 mg/mL and infused over 1--2 hours, with longer infusion times (3--6 hours) recommended for patients with azotemia, hyperkalemia, or those receiving high doses (>1 mg/kg) 1.
  • Premedication with acetaminophen or diphenhydramine may alleviate febrile reactions, which are less frequent in children than adults 1.
  • Laboratory monitoring orders for renal function, electrolytes (particularly potassium and magnesium), and complete blood counts should be included to mitigate the risk of nephrotoxicity and other adverse effects 1.

Special Considerations

  • For patients with life-threatening disease, the target daily dose should be administered from the beginning, while those with mild-to-moderate disease may have their dose increased as tolerated 1.
  • Amphotericin B lipid formulations may be considered for patients who are intolerant of conventional amphotericin B, have disseminated candidal infection that is refractory to conventional amphotericin B, or are at high risk for nephrotoxicity 1.
  • The duration of therapy should be determined by the presence of deep tissue foci, patient clinical response, and presence of neutropenia, with treatment recommended until 2--3 weeks after the last positive blood culture and signs and symptoms have resolved for candidemia 1.

From the Research

Protocol for Ordering Amphotericin B

To order amphotericin B, the following steps should be considered:

  • The usual daily maintenance dose of amphotericin B is 0.5-1 mg/kg i.v. 2
  • The manufacturer recommends beginning intravenous therapy with a 1-mg test dose 2
  • Amphotericin B can be infused over one to two hours (less than or equal to 50 mg/hr) in patients with adequate renal function 2
  • Ancillary medications administered to treat infusion-related adverse events should be used as prophylaxis in patients with a history of hypersensitivity or unacceptable reactions and as needed for relief of symptoms 2

Preparation and Administration

When preparing and administering amphotericin B:

  • Intravenous admixtures of amphotericin B 0.25 and 1.4 mg/mL in 5% dextrose injection have an expiration date of 35 days and 36 hours, respectively 2
  • Admixtures should be stored at 4-8 degrees C, and protection from fluorescent light is unnecessary 2
  • Admixtures may be prepared in polyolefin, glass, or polyvinyl chloride intravenous containers; certain evacuated intravenous containers contain buffers that can cause precipitation of amphotericin B 2

Considerations

It is essential to consider the following:

  • Amphotericin B has been the standard of care for most invasive fungal infections, but its use is often associated with low efficacy and poor tolerance 3
  • The antifungal armamentarium has increased with the addition of several new agents, including lipid formulations of amphotericin B, voriconazole, caspofungin, and micafungin 3
  • The characteristics of these new agents, such as spectrum, pharmacokinetic profile, route of administration, efficacy in clinical trials, safety profile, drug-drug interactions, and cost, should be reviewed to help clinicians select an antifungal agent for their patients 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Practical guidelines for preparing and administering amphotericin B.

American journal of hospital pharmacy, 1992

Research

Management of systemic fungal infections: alternatives to itraconazole.

The Journal of antimicrobial chemotherapy, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.